Blade Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

South San Francisco, CA – August 1, 2019 – Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019 at 2:30 p.m. Eastern Time.

About Blade Therapeutics

Blade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade’s lead compound, BLD-2660, is a highly selective calpain inhibitor targeted for the treatment of chronic fibrotic diseases. BLD-2660 is in a Phase I, healthy volunteer, dose escalation study in Australia, and the Company plans to submit an Investigational New Drug (IND) application to the U.S. FDA and initiate a Phase II trial in patients with liver fibrosis by year-end 2019. Blade has assembled a critical mass of anti-fibrotic drug development expertise within its top-tier leadership team and a world-class network of advisors. Lead investors in Blade include MPM Capital, Deerfield, Pfizer Ventures, One Ventures, Osage Partners, Bristol-Myers Squibb and Novartis Institute of Biomedical Research. Please visit for more information.


Blade Therapeutics
Wendye Robbins, M.D., President and CEO

Burns McClellan
Cameron Radinovic


Learn More

Our Team

Learn More


Learn More